Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13841508 | 1.00 | ALDH1A1 (0.34) | ALDH1A1LMNATP53CYP3A4HPGD | |
| SCHEMBL7351659 | 1.00 | ALDH1A1 (0.34) | ALDH1A1LMNATP53CYP3A4HPGD | |
| SCHEMBL9427362 | 1.00 | ALDH1A1 (0.34) | ALDH1A1LMNATP53CYP3A4HPGD | |
| SCHEMBL7351648 | 1.00 | ALDH1A1 (0.34) | ALDH1A1LMNATP53CYP3A4HPGD | |
| SCHEMBL25140702 | 0.73 | — | — | |
| SCHEMBL7506865 | 0.71 | — | — | |
| SCHEMBL7508694 | 0.71 | — | — | |
| SCHEMBL14435544 | 0.70 | — | — | |
| SCHEMBL3387123 | 0.70 | — | — | |
| SCHEMBL13309236 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4522583-A2 | PI3K ALPHA INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220131-A2 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-9823563-B2 | Alcohol compound and method for producing same, method for producing lactone compound, (meth)acrylate ester and method for producing same, polymer and method for producing same, and resist composition and method for producing substrate using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-11-21 | — | — | US | disclosed |
| US-9823563-B2 | Alcohol compound and method for producing same, method for producing lactone compound, (meth)acrylate ester and method for producing same, polymer and method for producing same, and resist composition and method for producing substrate using same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-11-21 | — | — | US | disclosed |
| EP-2636665-B1 | METHOD FOR PRODUCING ESTER | UNIV NAGOYA NAT UNIV CORP (JP) | 2016-06-22 | — | — | EP | disclosed |
| US-20140134539-A1 | ALCOHOL COMPOUND AND METHOD FOR PRODUCING SAME, METHOD FOR PRODUCING LACTONE COMPOUND, (METH)ACRYLATE ESTER AND METHOD FOR PRODUCING SAME, POLYMER AND METHOD FOR PRODUCING SAME, AND RESIST COMPOSITION AND METHOD FOR PRODUCING SUBSTRATE USING SAME | MITSUBISHI RAYON CO., LTD. (JP) | 2014-05-15 | — | — | US | disclosed |
| US-20140134539-A1 | ALCOHOL COMPOUND AND METHOD FOR PRODUCING SAME, METHOD FOR PRODUCING LACTONE COMPOUND, (METH)ACRYLATE ESTER AND METHOD FOR PRODUCING SAME, POLYMER AND METHOD FOR PRODUCING SAME, AND RESIST COMPOSITION AND METHOD FOR PRODUCING SUBSTRATE USING SAME | MITSUBISHI RAYON CO., LTD. (JP) | 2014-05-15 | — | — | US | disclosed |
| EP-2636665-A1 | METHOD FOR PRODUCING ESTER | National University Corporation Nagoya University (JP) | 2013-09-11 | — | — | EP | disclosed |
| EP-1352904-B1 | (METH)ACRYLATE ESTERS, STARTING ALCOHOLS FOR THE PREPARATION THEREOF, PROCESSES FOR PREPARING BOTH, POLYMERS OF THE ESTERS, CHEMICALLY AMPLIFIABLE RESIST COMPOSITIONS, AND METHOD FOR FORMING PATTERNS | MITSUBISHI RAYON CO (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-7339014-B2 | (Meth)acrylate, raw material alcohol for the (meth)acrylate, method of producing the (meth)acrylate and the alcohol, polymer produced by polymerizing the (meth)acrylate, chemically amplified resist composition, and method of the formation of a pattern | MITSUBISHI RAYON CO., LTD. (JP) | 2008-03-04 | — | — | US | disclosed |
| US-7339014-B2 | (Meth)acrylate, raw material alcohol for the (meth)acrylate, method of producing the (meth)acrylate and the alcohol, polymer produced by polymerizing the (meth)acrylate, chemically amplified resist composition, and method of the formation of a pattern | MITSUBISHI RAYON CO., LTD. (JP) | 2008-03-04 | — | — | US | disclosed |
| US-20070117993-A1 | Novel multicomponent oxidation catalyst and process for producing epoxy compound therewith | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-0940390-B1 | [6-(Substituted-methyl)-3-cyclohexenyl]formamide derivative, hair growth promoter and external composition for skin | SHISEIDO CO LTD (JP) | 2002-07-17 | — | — | EP | disclosed |
| US-6376539-B1 | ANTIISCHEMIC AGENTS, CENTRAL NERVOUS SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-23 | — | — | US | disclosed |
| US-6174885-B1 | IMPROVEMENT OR PREVENTION OF HAIR LOSS IN MAMMALS AND, IN PARTICULAR, IN HUMAN | SHISEIDO CO., LTD. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-1047686-A1 | SUBSTITUTED BICYCLIC LACTONES | Bayer Aktiengesellschaft (DE) | 2000-11-02 | — | — | EP | disclosed |
| EP-0940390-A1 | 6- (Substituted-methyl) -3- cyclohexenyl formamide derivative, hair growth promoter and external composition for skin | SHISEIDO COMPANY LIMITED (JP) | 1999-09-08 | — | — | EP | disclosed |
| WO-1999036418-A1 | SUBSTITUTED BICYCLIC LACTONES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | ALDH1A1 3698/4885LMNA 2874/4885TP53 747/4885 |
| US-20070117993-A1 | Novel multicomponent oxidation catalyst and process for producing epoxy compound therewith | HAO2, OSTC, HAAO | ALDH1A1 2186/4885LMNA 4852/4885TP53 3999/4885 |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CD, PIK3CG, PIK3CB | ALDH1A1 4597/4885LMNA 4174/4885TP53 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.